VFEND Side Effects
Generic Name: Voriconazole
Please note - some side effects for VFEND may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).
|
For the consumer For the professional
|
|
Side Effects of VFEND - for the consumer
Vfend
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Vfend:
Seek medical attention right away if any of these SEVERE side effects occur when using Vfend:Blurred vision; change in color perception; diarrhea; dizziness; headache; mental or mood changes; nausea; sensitivity to light; sensitivity to the sun; stomach pain; vomiting.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); black, tarry stools; chest pain; dark urine; decreased urination; depression; fast or irregular heartbeat; fever or chills; flushing; hallucinations; one-sided weakness; pain or numbness of an arm or leg; red, swollen, or blistered skin; seizures; severe stomach pain; shortness of breath; speech changes; sudden, severe headache, nausea, dizziness, or fainting; suicidal thoughts; swelling of the arms or legs; unusual bruising or bleeding; unusual fatigue; unusual vaginal bleeding; yellowing of the eyes or skin.
Vfend Suspension
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Vfend Suspension:
Seek medical attention right away if any of these SEVERE side effects occur when using Vfend Suspension:Blurred vision; change in color perception; diarrhea; dizziness; headache; mental or mood changes; nausea; sensitivity to light; sensitivity to the sun; stomach pain; vomiting.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); black, tarry stools; chest pain; dark urine; decreased urination; depression; fast or irregular heartbeat; fever or chills; flushing; hallucinations; one-sided weakness; pain or numbness of an arm or leg; red, swollen, or blistered skin; seizures; severe stomach pain; shortness of breath; speech changes; sudden, severe headache, nausea, dizziness, or fainting; suicidal thoughts; swelling of the arms or legs; unusual bruising or bleeding; unusual fatigue; unusual vaginal bleeding; yellowing of the eyes or skin.
Vfend Tablets
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Vfend Tablets:
Seek medical attention right away if any of these SEVERE side effects occur when using Vfend Tablets:Blurred vision; change in color perception; diarrhea; dizziness; headache; mental or mood changes; nausea; sensitivity to light; sensitivity to the sun; stomach pain; vomiting.
TopSevere allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); black, tarry stools; chest pain; dark urine; decreased urination; depression; fast or irregular heartbeat; fever or chills; flushing; hallucinations; one-sided weakness; pain or numbness of an arm or leg; red, swollen, or blistered skin; seizures; severe stomach pain; shortness of breath; speech changes; sudden, severe headache, nausea, dizziness, or fainting; suicidal thoughts; swelling of the arms or legs; unusual bruising or bleeding; unusual fatigue; unusual vaginal bleeding; yellowing of the eyes or skin.
For the professional
Vfend
Overview
The most frequently reported adverse events (all causalities) in the therapeutic trials were visual disturbances, fever, rash, vomiting, nausea, diarrhea, headache, sepsis, peripheral edema, abdominal pain, and respiratory disorder. The treatment-related adverse events which most often led to discontinuation of voriconazole therapy were elevated liver function tests, rash, and visual disturbances.
Discussion of Adverse Reactions
The data described in Table 11 reflect exposure to voriconazole in 1655 patients in the therapeutic studies. This represents a heterogeneous population, including immunocompromised patients, e.g., patients with hematological malignancy or HIV and non-neutropenic patients. This subgroup does not include healthy volunteers and patients treated in the compassionate use and non-therapeutic studies. This patient population was 62% male, had a mean age of 46 years (range 11–90, including 51 patients aged 12–18 years), and was 78% white and 10% black. In the initial regulatory filing, 561 patients had a duration of voriconazole therapy of greater than 12 weeks, with 136 patients receiving voriconazole for over six months. Table 11 includes all adverse events which were reported at an incidence of ≥2% during voriconazole therapy in the all therapeutic studies population, studies 307/602 and 608 combined, or study 305, as well as events of concern which occurred at an incidence of <2%.
In study 307/602, 381 patients (196 on voriconazole, 185 on amphotericin B) were treated to compare voriconazole to amphotericin B followed by other licensed antifungal therapy in the primary treatment of patients with acute invasive aspergillosis. In study 608, 403 patients with candidemia were treated to compare voriconazole (272 patients) to the regimen of amphotericin B followed by fluconazole (131 patients). Study 305 evaluated the effects of oral voriconazole (200 patients) and oral fluconazole (191 patients) in the treatment of esophageal candidiasis. Laboratory test abnormalities for these studies are discussed under Clinical Laboratory Values below.
| Rate ≥ 2% on Voriconazole or Adverse Events of Concern in All Therapeutic Studies Population, Studies 307/602–608 Combined, or Study 305. Possibly Related to Therapy or Causality Unknown* | ||||||
|---|---|---|---|---|---|---|
| All Therapeutic Studies | Studies 307/602 and 608 (IV/ oral therapy) | Study 305 (oral therapy) | ||||
| Voriconazole N = 1655 |
Voriconazole N = 468 |
Ampho B† N=185 |
Ampho B→ Fluconazole N= 131 |
Voriconazole N = 200 |
Fluconazole N =191 |
|
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
| ||||||
| Special Senses‡ | ||||||
| Abnormal vision | 310 (18.7) | 63 (13.5) | 1 (0.5) | 0 | 31 (15.5) | 8 (4.2) |
| Photophobia | 37 (2.2) | 8 (1.7) | 0 | 0 | 5 (2.5) | 2 (1.0) |
| Chromatopsia | 20 (1.2) | 2 (0.4) | 0 | 0 | 2 (1.0) | 0 |
| Body as a Whole | ||||||
| Fever | 94 (5.7) | 8 (1.7) | 25 (13.5) | 5 (3.8) | 0 | 0 |
| Chills | 61 (3.7) | 1 (0.2) | 36 (19.5) | 8 (6.1) | 1 (0.5) | 0 |
| Headache | 49 (3.0) | 9 (1.9) | 8 (4.3) | 1 (0.8) | 0 | 1 (0.5) |
| Cardiovascular System | ||||||
| Tachycardia | 39 (2.4) | 6 (1.3) | 5 (2.7) | 0 | 0 | 0 |
| Digestive System | ||||||
| Nausea | 89 (5.4) | 18 (3.8) | 29 (15.7) | 2 (1.5) | 2 (1.0) | 3 (1.6) |
| Vomiting | 72 (4.4) | 15 (3.2) | 18 (9.7) | 1 (0.8) | 2 (1.0) | 1 (0.5) |
| Liver function tests abnormal | 45 (2.7) | 15 (3.2) | 4 (2.2) | 1 (0.8) | 6 (3.0) | 2 (1.0) |
| Cholestatic jaundice | 17 (1.0) | 8 (1.7) | 0 | 1 (0.8) | 3 (1.5) | 0 |
| Metabolic and Nutritional Systems | ||||||
| Alkaline phosphatase increased | 59 (3.6) | 19 (4.1) | 4 (2.2) | 3 (2.3) | 10 (5.0) | 3 (1.6) |
| Hepatic enzymes increased | 30 (1.8) | 11 (2.4) | 5 (2.7) | 1 (0.8) | 3 (1.5) | 0 |
| SGOT increased | 31 (1.9) | 9 (1.9) | 0 | 1 (0.8) | 8 (4.0) | 2 (1.0) |
| SGPT increased | 29 (1.8) | 9 (1.9) | 1 (0.5) | 2 (1.5) | 6 (3.0) | 2 (1.0) |
| Hypokalemia | 26 (1.6) | 3 (0.6) | 36 (19.5) | 16 (12.2) | 0 | 0 |
| Bilirubinemia | 15 (0.9) | 5 (1.1) | 3 (1.6) | 2 (1.5) | 1 (0.5) | 0 |
| Creatinine increased | 4 (0.2) | 0 | 59 (31.9) | 10 (7.6) | 1 (0.5) | 0 |
| Nervous System | ||||||
| Hallucinations | 39 (2.4) | 13 (2.8) | 1 (0.5) | 0 | 0 | 0 |
| Skin and Appendages | ||||||
| Rash | 88 (5.3) | 20 (4.3) | 7 (3.8) | 1 (0.8) | 3 (1.5) | 1 (0.5) |
| Urogenital | ||||||
| Kidney function abnormal | 10 (0.6) | 6 (1.3) | 40 (21.6) | 9 (6.9) | 1 (0.5) | 1 (0.5) |
| Acute kidney failure | 7 (0.4) | 2 (0.4) | 11 (5.9) | 7 (5.3) | 0 | 0 |
Voriconazole treatment-related visual disturbances are common. In therapeutic trials, approximately 21% of patients experienced abnormal vision, color vision change and/or photophobia. The visual disturbances were generally mild and rarely resulted in discontinuation. Visual disturbances may be associated with higher plasma concentrations and/or doses.
The mechanism of action of the visual disturbance is unknown, although the site of action is most likely to be within the retina. In a study in healthy volunteers investigating the effect of 28-day treatment with voriconazole on retinal function, voriconazole caused a decrease in the electroretinogram (ERG) waveform amplitude, a decrease in the visual field, and an alteration in color perception. The ERG measures electrical currents in the retina. The effects were noted early in administration of voriconazole and continued through the course of study drug dosing. Fourteen days after end of dosing, ERG, visual fields and color perception returned to normal.
Dermatological Reactions
Dermatological reactions were common in the patients treated with voriconazole. The mechanism underlying these dermatologic adverse events remains unknown. In clinical trials, rashes considered related to therapy were reported by 7% (110/1655) of voriconazole-treated patients. The majority of rashes were of mild to moderate severity. Cases of photosensitivity reactions appear to be more likely to occur with long-term treatment. Patients have rarely developed serious cutaneous reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme during treatment with Vfend. If patients develop a rash, they should be monitored closely and consideration given to discontinuation of Vfend. It is recommended that patients avoid strong, direct sunlight during Vfend therapy.
Less Common Adverse Events
The following adverse events occurred in < 2% of all voriconazole-treated patients in all therapeutic studies (N=1655). This listing includes events where a causal relationship to voriconazole cannot be ruled out or those which may help the physician in managing the risks to the patients. The list does not include events included in Table 11 above and does not include every event reported in the voriconazole clinical program.
Body as a Whole: abdominal pain, abdomen enlarged, allergic reaction, anaphylactoid reaction, ascites, asthenia, back pain, chest pain, cellulitis, edema, face edema, flank pain, flu syndrome, graft versus host reaction, granuloma, infection, bacterial infection, fungal infection, injection site pain, injection site infection/inflammation, mucous membrane disorder, multi-organ failure, pain, pelvic pain, peritonitis, sepsis, substernal chest pain
Cardiovascular: atrial arrhythmia, atrial fibrillation, AV block complete, bigeminy, bradycardia, bundle branch block, cardiomegaly, cardiomyopathy, cerebral hemorrhage, cerebral ischemia, cerebrovascular accident, congestive heart failure, deep thrombophlebitis, endocarditis, extrasystoles, heart arrest, hypertension, hypotension, myocardial infarction, nodal arrhythmia, palpitation, phlebitis, postural hypotension, pulmonary embolus, QT interval prolonged, supraventricular extrasystoles, supraventricular tachycardia, syncope, thrombophlebitis, vasodilatation, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia (including torsade de pointes)
Digestive: anorexia, cheilitis, cholecystitis, cholelithiasis, constipation, diarrhea, duodenal ulcer perforation, duodenitis, dyspepsia, dysphagia, dry mouth, esophageal ulcer, esophagitis, flatulence, gastroenteritis, gastrointestinal hemorrhage, GGT/LDH elevated, gingivitis, glossitis, gum hemorrhage, gum hyperplasia, hematemesis, hepatic coma, hepatic failure, hepatitis, intestinal perforation, intestinal ulcer, jaundice, enlarged liver, melena, mouth ulceration, pancreatitis, parotid gland enlargement, periodontitis, proctitis, pseudomembranous colitis, rectal disorder, rectal hemorrhage, stomach ulcer, stomatitis, tongue edema
Endocrine: adrenal cortex insufficiency, diabetes insipidus, hyperthyroidism, hypothyroidism
Hemic and Lymphatic: agranulocytosis, anemia (macrocytic, megaloblastic, microcytic, normocytic), aplastic anemia, hemolytic anemia, bleeding time increased, cyanosis, DIC, ecchymosis, eosinophilia, hypervolemia, leukopenia, lymphadenopathy, lymphangitis, marrow depression, pancytopenia, petechia, purpura, enlarged spleen, thrombocytopenia, thrombotic thrombocytopenic purpura
Metabolic and Nutritional: albuminuria, BUN increased, creatine phosphokinase increased, edema, glucose tolerance decreased, hypercalcemia, hypercholesteremia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hyperuricemia, hypocalcemia, hypoglycemia, hypomagnesemia, hyponatremia, hypophosphatemia, peripheral edema, uremia
Musculoskeletal: arthralgia, arthritis, bone necrosis, bone pain, leg cramps, myalgia, myasthenia, myopathy, osteomalacia, osteoporosis
Nervous System: abnormal dreams, acute brain syndrome, agitation, akathisia, amnesia, anxiety, ataxia, brain edema, coma, confusion, convulsion, delirium, dementia, depersonalization, depression, diplopia, dizziness, encephalitis, encephalopathy, euphoria, Extrapyramidal Syndrome, grand mal convulsion, Guillain-Barré syndrome, hypertonia, hypesthesia, insomnia, intracranial hypertension, libido decreased, neuralgia, neuropathy, nystagmus, oculogyric crisis, paresthesia, psychosis, somnolence, suicidal ideation, tremor, vertigo
Respiratory System: cough increased, dyspnea, epistaxis, hemoptysis, hypoxia, lung edema, pharyngitis, pleural effusion, pneumonia, respiratory disorder, respiratory distress syndrome, respiratory tract infection, rhinitis, sinusitis, voice alteration
Skin and Appendages: alopecia, angioedema, contact dermatitis, discoid lupus erythematosis, eczema, erythema multiforme, exfoliative dermatitis, fixed drug eruption, furunculosis, herpes simplex, maculopapular rash, melanosis, photosensitivity skin reaction, pruritus, psoriasis, skin discoloration, skin disorder, skin dry, Stevens-Johnson syndrome, sweating, toxic epidermal necrolysis, urticaria
Special Senses: abnormality of accommodation, blepharitis, color blindness, conjunctivitis, corneal opacity, deafness, ear pain, eye pain, eye hemorrhage, dry eyes, hypoacusis, keratitis, keratoconjunctivitis, mydriasis, night blindness, optic atrophy, optic neuritis, otitis externa, papilledema, retinal hemorrhage, retinitis, scleritis, taste loss, taste perversion, tinnitus, uveitis, visual field defect
Urogenital: anuria, blighted ovum, creatinine clearance decreased, dysmenorrhea, dysuria, epididymitis, glycosuria, hemorrhagic cystitis, hematuria, hydronephrosis, impotence, kidney pain, kidney tubular necrosis, metrorrhagia, nephritis, nephrosis, oliguria, scrotal edema, urinary incontinence, urinary retention, urinary tract infection, uterine hemorrhage, vaginal hemorrhage
Clinical Laboratory Values
The overall incidence of clinically significant transaminase abnormalities in all therapeutic studies was 12.4% (206/1655) of patients treated with voriconazole. Increased incidence of liver function test abnormalities may be associated with higher plasma concentrations and/or doses. The majority of abnormal liver function tests either resolved during treatment without dose adjustment or following dose adjustment, including discontinuation of therapy.
Voriconazole has been infrequently associated with cases of serious hepatic toxicity including cases of jaundice and rare cases of hepatitis and hepatic failure leading to death. Most of these patients had other serious underlying conditions.
Liver function tests should be evaluated at the start of and during the course of Vfend therapy. Patients who develop abnormal liver function tests during Vfend therapy should be monitored for the development of more severe hepatic injury. Patient management should include laboratory evaluation of hepatic function (particularly liver function tests and bilirubin). Discontinuation of Vfend must be considered if clinical signs and symptoms consistent with liver disease develop that may be attributable to Vfend.
Acute renal failure has been observed in severely ill patients undergoing treatment with Vfend. Patients being treated with voriconazole are likely to be treated concomitantly with nephrotoxic medications and have concurrent conditions that may result in decreased renal function. It is recommended that patients are monitored for the development of abnormal renal function. This should include laboratory evaluation, particularly serum creatinine.
Tables 12 and 13 and 14 show the number of patients with hypokalemia and clinically significant changes in renal and liver function tests in three randomized, comparative multicenter studies. In study 305, patients with esophageal candidiasis were randomized to either oral voriconazole or oral fluconazole. In study 307/602, patients with definite or probable invasive aspergillosis were randomized to either voriconazole or amphotericin B therapy. In study 608, patients with candidemia were randomized to either voriconazole or the regimen of amphotericin B followed by fluconazole.
| Criteria* | Voriconazole | Fluconazole | |
|---|---|---|---|
| n/N (%) | n /N (%) | ||
| n number of patients with a clinically significant abnormality while on study therapy | |||
| N total number of patients with at least one observation of the given lab test while on study therapy | |||
| ULN upper limit of normal | |||
| |||
| T. Bilirubin | >1.5× ULN | 8/185 (4.3) | 7/186 (3.8) |
| AST | >3.0× ULN | 38/187 (20.3) | 15/186 (8.1) |
| ALT | >3.0× ULN | 20/187 (10.7) | 12/186 (6.5) |
| Alk phos | >3.0× ULN | 19/187 (10.2) | 14/186 (7.5) |
| Criteria* | Voriconazole | Amphotericin B† | |
|---|---|---|---|
| n/N (%) | n /N (%) | ||
| n number of patients with a clinically significant abnormality while on study therapy | |||
| N total number of patients with at least one observation of the given lab test while on study therapy | |||
| ULN upper limit of normal | |||
| LLN lower limit of normal | |||
| T. Bilirubin | >1.5× ULN | 35/180 (19.4) | 46/173 (26.6) |
| AST | >3.0× ULN | 21/180 (11.7) | 18/174 (10.3) |
| ALT | >3.0× ULN | 34/180 (18.9) | 40/173 (23.1) |
| Alk phos | >3.0× ULN | 29/181 (16.0) | 38/173 (22.0) |
| Creatinine | >1.3× ULN | 39/182 (21.4) | 102/177 (57.6) |
| Potassium | <0.9× LLN | 30/181 (16.6) | 70/178 (39.3) |
| Criteria* | Voriconazole | Amphotericin B followed by Fluconazole | |
|---|---|---|---|
| n/N (%) | n /N (%) | ||
| n number of patients with a clinically significant abnormality while on study therapy | |||
| N total number of patients with at least one observation of the given lab test while on study therapy | |||
| ULN upper limit of normal | |||
| LLN lower limit of normal | |||
| |||
| T. Bilirubin | >1.5× ULN | 50/261 (19.2) | 31/115 (27.0) |
| AST | >3.0× ULN | 40/261 (15.3) | 16/116 (13.8) |
| ALT | >3.0× ULN | 22/261 (8.4) | 15/116 (12.9) |
| Alk phos | >3.0× ULN | 59/261 (22.6) | 26/115 (22.6) |
| Creatinine | >1.3× ULN | 39/260 (15.0) | 32/118 (27.1) |
| Potassium | <0.9× LLN | 43/258 (16.7) | 35/118 (29.7) |
More resources:
VFEND - Includes detailed dosage instructions.
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
